18 February 2022
EMA/102067/2022
EMEA/H/C/002380

Public statement

Leganto

Withdrawal of the marketing authorisation in the European Union

On 14 December 2021, the European Commission withdrew the marketing authorisation for Leganto (rotigotine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, UCB Pharma S.A., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Leganto was granted marketing authorisation in the EU on 16 June 2011 for the treatment of restless legs syndrome and Parkinson´s disease. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2016.

Leganto was a duplicate of Neupro, which is marketed in several EU countries.

The European Public Assessment Report (EPAR) for Leganto will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union